Afami-cel is made by collecting a patient’s T-cells, genetically modifying them and infusing them back into the patient, according to an Aug. 27 National Cancer Institute news release. The treatment has been approved for people with metastatic synovial sarcoma who have been treated with chemotherapy and whose tumors are positive for the presence of MAGE-A4 and a certain HLA proteins.
In a trial of 44 patients, 43% saw a shrinkage in their tumors that lasted an average of six months.
This T-cell therapy is similar to CAR-T cell therapies already approved by the FDA, according to the release.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.